亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Optimal sequencing of ibrutinib, idelalisib, and venetoclax in chronic lymphocytic leukemia: results from a multicenter study of 683 patients

伊布替尼 威尼斯人 医学 伊德里希 慢性淋巴细胞白血病 肿瘤科 内科学 白血病
作者
Anthony R. Mato,Brian T. Hill,Nicole Lamanna,Paul M. Barr,Chaitra S. Ujjani,Danielle M. Brander,Cullan Howlett,Alan P Skarbnik,Bruce D. Cheson,Clive S. Zent,Jeffrey J. Pu,Pavel Kiselev,Kenneth A. Foon,Jonas Lenhart,Spencer Henick Bachow,Allison Winter,Allan-Louie Cruz,David F. Claxton,André Goy,Catherine Daniel
出处
期刊:Annals of Oncology [Elsevier BV]
卷期号:28 (5): 1050-1056 被引量:225
标识
DOI:10.1093/annonc/mdx031
摘要

BackgroundIbrutinib, idelalisib, and venetoclax are approved for treating CLL patients in the United States. However, there is no guidance as to their optimal sequence.Patients and methodsWe conducted a multicenter, retrospective analysis of CLL patients treated with kinase inhibitors (KIs) or venetoclax. We examined demographics, discontinuation reasons, overall response rates (ORR), survival, and post-KI salvage strategies. Primary endpoint was progression-free survival (PFS).ResultsA total of 683 patients were identified. Baseline characteristics were similar in the ibrutinib and idelalisib groups. ORR to ibrutinib and idelalisib as first KI was 69% and 81%, respectively. With a median follow-up of 17 months (range 1–60), median PFS and OS for the entire cohort were 35 months and not reached. Patients treated with ibrutinib (versus idelalisib) as first KI had a significantly better PFS in all settings; front-line [hazard ratios (HR) 2.8, CI 1.3–6.3, P = 0.01], relapsed-refractory (HR 2.8, CI 1.9–4.1, P < 0.001), del17p (HR 2.0, CI 1.2–3.4, P = 0.008), and complex karyotype (HR 2.5, CI 1.2–5.2, P = 0.02). At the time of initial KI failure, use of an alternate KI or venetoclax had a superior PFS when compared with chemoimmunotherapy. Furthermore, patients who discontinued ibrutinib due to progression or toxicity had marginally improved outcomes if they received venetoclax (ORR 79%) versus idelalisib (ORR 46%) (PFS HR .6, CI.3–1.0, P = 0.06).ConclusionsIn the largest real-world experience of novel agents in CLL, ibrutinib appears superior to idelalisib as first KI. Furthermore, in the setting of KI failure, alternate KI or venetoclax therapy appear superior to chemoimmunotherapy combinations. The use of venetoclax upon ibrutinib failure might be superior to idelalisib. These data support the need for trials testing sequencing strategies to optimize treatment algorithms. Ibrutinib, idelalisib, and venetoclax are approved for treating CLL patients in the United States. However, there is no guidance as to their optimal sequence. We conducted a multicenter, retrospective analysis of CLL patients treated with kinase inhibitors (KIs) or venetoclax. We examined demographics, discontinuation reasons, overall response rates (ORR), survival, and post-KI salvage strategies. Primary endpoint was progression-free survival (PFS). A total of 683 patients were identified. Baseline characteristics were similar in the ibrutinib and idelalisib groups. ORR to ibrutinib and idelalisib as first KI was 69% and 81%, respectively. With a median follow-up of 17 months (range 1–60), median PFS and OS for the entire cohort were 35 months and not reached. Patients treated with ibrutinib (versus idelalisib) as first KI had a significantly better PFS in all settings; front-line [hazard ratios (HR) 2.8, CI 1.3–6.3, P = 0.01], relapsed-refractory (HR 2.8, CI 1.9–4.1, P < 0.001), del17p (HR 2.0, CI 1.2–3.4, P = 0.008), and complex karyotype (HR 2.5, CI 1.2–5.2, P = 0.02). At the time of initial KI failure, use of an alternate KI or venetoclax had a superior PFS when compared with chemoimmunotherapy. Furthermore, patients who discontinued ibrutinib due to progression or toxicity had marginally improved outcomes if they received venetoclax (ORR 79%) versus idelalisib (ORR 46%) (PFS HR .6, CI.3–1.0, P = 0.06). In the largest real-world experience of novel agents in CLL, ibrutinib appears superior to idelalisib as first KI. Furthermore, in the setting of KI failure, alternate KI or venetoclax therapy appear superior to chemoimmunotherapy combinations. The use of venetoclax upon ibrutinib failure might be superior to idelalisib. These data support the need for trials testing sequencing strategies to optimize treatment algorithms.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
7秒前
aspect完成签到 ,获得积分10
19秒前
nk完成签到 ,获得积分10
21秒前
31秒前
开心惜梦完成签到,获得积分10
32秒前
33秒前
123完成签到,获得积分10
35秒前
粗暴的画板完成签到,获得积分10
49秒前
冷傲的醉山完成签到,获得积分10
53秒前
56秒前
合适的飞绿完成签到,获得积分10
1分钟前
1分钟前
健忘盼柳完成签到,获得积分10
1分钟前
1分钟前
馆长举报kento的求助涉嫌违规
1分钟前
神勇寄风完成签到,获得积分10
2分钟前
2分钟前
善良的金鱼完成签到,获得积分10
2分钟前
2分钟前
2分钟前
可爱的函函的应助被闪闪灵雁采纳,获得10
2分钟前
zoeyluo完成签到,获得积分20
2分钟前
怕孤独的梦寒完成签到,获得积分10
2分钟前
2分钟前
研友_nxw2xL完成签到,获得积分0
3分钟前
3分钟前
幸福猎豹完成签到,获得积分10
3分钟前
yang1316发布了新的文献求助10
3分钟前
喜悦的唇彩完成签到,获得积分10
3分钟前
3分钟前
uss完成签到,获得积分10
3分钟前
专注的夜天完成签到,获得积分10
3分钟前
3分钟前
和谐寻云完成签到,获得积分10
3分钟前
4分钟前
无极微光的应助被生气来找我采纳,获得20
4分钟前
车访枫完成签到,获得积分10
4分钟前
阔达的沛岚完成签到,获得积分10
4分钟前
称心的忆山完成签到,获得积分10
4分钟前
4分钟前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
Social Psychology in the Real World 600
八旗制度の研究 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8179889
求助须知:如何正确求助?哪些是违规求助? 9570071
关于积分的说明 21808307
捐赠科研通 7775682
什么是DOI,文献DOI怎么找? 3433193
关于科研通互助平台的介绍 2557334
邀请新用户注册赠送积分活动 2478881